References
- AgarwalRNissensonARBatlleDCoyneDWTroutJRWarnockDGPrevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United StatesAm J Med2003115429129712967694
- CollinsAJRobertsTLSt PeterWLChenSCEbbenJConstantiniEUnited States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelinesAm J Kidney Dis200239478479511920345
- HerzogCAMaJZCollinsAJLong-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified?Circulation2002105111336134111901045
- AgarwalRSinhaADCardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysisHypertension200953586086619273737
- HeerspinkHJNinomiyaTZoungasSEffect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trialsLancet200937396681009101519249092
- BlankestijnPJLigtenbergGVolume-independent mechanisms of hypertension in hemodialysis patients: clinical implicationsSemin Dial200417426526915250915
- LaraghJHRenin profiling for diagnosis, risk assessment, and treatment of hypertensionKidney Int1993445116311758264150
- MatsumotoNIshimitsuTOkamuraASetaHTakahashiMMatsuokaHEffects of imidapril on left ventricular mass in chronic hemodialysis patientsHypertens Res200629425326016778332
- WautersJPWaeberBBrunnerHRGuignardJPTuriniGAGavrasHUncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtractionClin Nephrol198116286926266727
- SarachoRMartin-MaloAMartinezIAljamaPMontenegroJEvaluation of the Losartan in Hemodialysis (ELHE) StudyKidney Int Suppl199868S125S1299839296
- ShibasakiYMasakiHNishiueTNishikawaMMatsubaraHIwasakaTAngiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal diseaseNephron200290325626111867945
- KannoYKanekoKKanekoMAngiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patientsJ Cardiovasc Pharmacol200443338038615076221
- MorishitaYKusanoEThe blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapyCardiovasc Hematol Agents Med Chem2011Epub Oct21
- MorishitaYHanawaSChindaJIimuraOTsunematsuSKusanoEEffects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertensionHypertens Res201134330831321124333
- EmanuelRLCainJPWilliamsGHDouble antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasmaJ Lab Clin Med19738146326404348744
- RodbardDStatistical quality control and routine data processing for radioimmunoassays and immunoradiometric assaysClin Chem19742010125512704370388
- CesaroneMRBelcaroGCarratelliMA simple test to monitor oxidative stressInt Angiol199918212713010424368
- GerardiGUsbertiMMartiniGPlasma total antioxidant capacity in hemodialyzed patients and its relationships to other biomarkers of oxidative stress and lipid peroxidationClin Chem Lab Med200240210411011939481
- LatiniRMassonSAnandIThe comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFTEur Heart J200425429229914984917
- LatiniRMassonSWongMIncremental prognostic value of changes in B-type natriuretic peptide in heart failureAm J Med2006119170e23e3016431191
- JourdainPJondeauGFunckFPlasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter StudyJ Am Coll Cardiol200749161733173917448376